Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longboard Pharmaceuticals Inc (NQ: LBPH ) 33.76 -3.02 (-8.22%) Streaming Delayed Price Updated: 3:48 PM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Longboard Pharmaceuticals Inc < Previous 1 2 Next > Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) July 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) July 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) June 10, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) June 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 06, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates May 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 April 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) April 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates March 12, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) March 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) February 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February February 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares January 08, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire This biotech stock has surged over 300% this week January 05, 2024 Shares of Longboard Pharmaceuticals (NASDAQ: LBPH) have sky-rocketed higher this week, up over 300% thanks to breaking news Via MarketBeat Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock January 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock January 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) January 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) January 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers November 29, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community November 21, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) November 03, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results November 02, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November November 01, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023 October 05, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023 September 19, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences August 31, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings August 30, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies August 23, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results August 03, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present at Upcoming Investor Conferences August 03, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.